Insider Buying: Establishment Labs Holdings Inc (NASDAQ:ESTA) Director Acquires 2,700 Shares of Stock

Establishment Labs Holdings Inc (NASDAQ:ESTA) Director Nicholas Sheridan Lewin acquired 2,700 shares of the stock in a transaction dated Monday, August 19th. The shares were bought at an average price of $20.11 per share, with a total value of $54,297.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Establishment Labs stock traded down $0.69 during mid-day trading on Monday, reaching $20.00. The stock had a trading volume of 128,664 shares, compared to its average volume of 63,236. The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.10 and a current ratio of 3.94. Establishment Labs Holdings Inc has a fifty-two week low of $19.61 and a fifty-two week high of $30.70. The stock’s 50-day simple moving average is $22.82 and its 200-day simple moving average is $24.36. The firm has a market capitalization of $410.00 million and a PE ratio of -17.86.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.08. Establishment Labs had a negative return on equity of 60.43% and a negative net margin of 38.63%. The firm had revenue of $21.68 million during the quarter, compared to analysts’ expectations of $20.10 million. On average, research analysts forecast that Establishment Labs Holdings Inc will post -1.97 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in ESTA. Wells Fargo & Company MN acquired a new stake in Establishment Labs in the second quarter valued at approximately $479,000. JPMorgan Chase & Co. lifted its holdings in shares of Establishment Labs by 96.3% in the second quarter. JPMorgan Chase & Co. now owns 13,014 shares of the company’s stock valued at $273,000 after purchasing an additional 6,386 shares in the last quarter. JW Asset Management LLC lifted its holdings in shares of Establishment Labs by 1,840.3% in the second quarter. JW Asset Management LLC now owns 3,104,485 shares of the company’s stock valued at $68,268,000 after purchasing an additional 2,944,485 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Establishment Labs by 257.1% in the second quarter. Tower Research Capital LLC TRC now owns 1,350 shares of the company’s stock valued at $30,000 after purchasing an additional 972 shares in the last quarter. Finally, Vanguard Group Inc. bought a new position in shares of Establishment Labs in the second quarter valued at approximately $349,000. 25.86% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have recently issued reports on the company. Stephens assumed coverage on Establishment Labs in a research report on Thursday, June 6th. They set an “overweight” rating and a $37.00 price objective for the company. ValuEngine raised Establishment Labs from a “hold” rating to a “buy” rating in a research note on Monday, July 29th. Wells Fargo & Co set a $29.00 target price on Establishment Labs and gave the stock a “buy” rating in a research note on Friday, July 12th. BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Establishment Labs in a research note on Thursday, May 16th. Finally, Zacks Investment Research cut Establishment Labs from a “hold” rating to a “sell” rating in a research note on Friday. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $35.33.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.

Featured Story: Stochastic Momentum Index (SMI)

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.